PharmaJet announced today that one of its pharmaceutical partners, Nykode Therapeutics, has begun a trial for a COVID-19 vaccine with PharmaJet’s needle-free injection technology. Nykode’s Phase 1/2 clinical trial will specifically address the emerging SARS-CoV-2 variants, with the DNA-based vaccines delivered intramuscularly with PharmaJet’s Stratis needle-free injection system. The vaccines are designed to be tailored […]
coronavirus
Aerogen inks partnership to deliver COVID-19 vaccine with its mesh aerosol delivery tech
Aerogen and CanSinoBio announced today that they entered a partnership to deliver the latter’s COVID-19 vaccine with Aerogen’s technology. Galway, Ireland-based Aerogen’s proprietary vibrating mesh aerosol drug delivery technology will be used to deliver CanSinoBio’s recombinant novel coronavirus vaccine — Convidecia — under the development and commercial supply partnership. Commercial terms for the partnership were […]
World faces a shortage of up to 2 billion COVID-19 vaccine syringes
The World Health Organization (WHO) reportedly warned that a massive shortage of syringes for COVID-19 vaccines could be on the horizon. Reuters reported that WHO expert Lisa Hedman told a United Nations briefing that the potential shortage of 1 billion to 2 billion syringes could slow down routine immunizations and create issues with needle safety […]
BD ticks up on Street-beating Q4, sets 2022 guidance range
BD (NYSE:BDX) shares rose today on fourth-quarter results that came in ahead of the consensus forecast. The Franklin Lakes, New Jersey-based medtech posted profits of $242 million, or 84¢ per share, on sales of $5.1 billion for the three months ended Sept. 30, 2021, more than doubling its bottom line on sales growth of 7.3%. Get […]
New BD syringe manufacturing lines are up and running in Nebraska
BD (NYSE:BDX) announced today that it increased its manufacturing capacity and domestic supply for syringes and needles. Franklin Lakes, N.J.-based BD’s new syringe and needle manufacturing lines, which were completed on an accelerated timeline, represent BD’s partnership with Department of Health and Human Services’ (HHS) Assistant Secretary for Preparedness and Response (ASPR). In July 2020, […]
BD says glass prefillable syringes still perform after deep cold storage
BD (NYSE:BDX) today shared the results from a preliminary study investigating the impact of deep cold storage on glass prefillable syringes. Franklin Lakes, N.J.-based BD’s study evaluated deep cold storage (-20°C and -40°C) as traditional vaccine formulations are commonly stored up to about 2°C to 8°C, while mRNA vaccine formulations (the type of COVID-19 vaccine […]
Scancell picks PharmaJet’s needle-free injection systems to deliver COVID-19 vaccine candidates
PharmaJet announced today that its partner, Scancell, chose its needle-free injection platform to administer its COVID-19 vaccine candidates. Scancell selected Golden, Colorado-based PharmaJet’s devices to administer two SARS-CoV-2 DNA-based vaccine candidates, SCOV1 and SCOV2. The vaccines will be exclusively administered using the PharmaJet Tropis and PharmaJet Stratis needle-free injection systems. According to a news release, […]
Overcoming vaccine delivery device design’s top challenges
Vaccine delivery has long been a hot topic and only got hotter in the ongoing push to vaccinate against COVID-19 around the world. Most would probably associate vaccines with the standard “jab” injection with a syringe. Over the past year and more, companies have touted ideas for other avenues. Inovio has a “smart” delivery device […]
Three companies to collaborate on potential inhaled COVID-19 treatment
Signal Rx Pharmaceuticals, Crystec and ADYA are working on a dry powder drug formulation for potentially treating COVID-19-related illness. The three companies’ collaboration for the dry powder formulation of SF2523 covers the treatment of pulmonary fibrosis, lung cancer and illnesses related to SARS-CoV-2, the virus causing COVID-19. SignalRx’s SF2523 is a novel, small-molecule, dual PI3K-BRD4 […]
Vaxart stock soars after FDA approves IND application for oral COVID-19 vaccine tablet
Vaxart (NSDQ:VXRT) announced today that the FDA cleared the investigational new drug (IND) application for its oral COVID-19 vaccine. Upon news of the IND application approval for the S-only protein construct-based vaccine candidate, shares of VXRT were up 16.1% at $8.35 in early-morning trading today. South San Francisco-based Vaxart’s S+N oral tablet SARS-CoV-2 vaccine candidate […]
